Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes-Reference-Cited by-同舟云学术

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

Published:2011-04 Issue:4 Volume:10 Page:338-348
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Coles Alasdair J,Fox Edward,Vladic Anton,Gazda Suzanne K,Brinar Vesna,Selmaj Krzysztof W,Bass Ann Doan-Do,Wynn Daniel R,Margolin David H,Lake Stephen L,Moran Susan,Palmer Jeffrey,Smith M Shelton,Compston D Alastair S

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference10 articles.

1. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis;Xia;Biochem J,1993

2. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis;Cox;Eur J Immunol,2005

3. B-cell reconstitution and BAFF after alemtuzumab;Thompson;J Clin Immunol,2010

4. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy;Coles;J Neurol,2006

5. Alemtuzumab vs interferon beta-1a in early multiple sclerosis;N Engl J Med,2008

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Typical and Emerging Diagnostic MRI Features in Multiple Sclerosis;Canadian Association of Radiologists Journal;2024-07-23

2. Multiple Sclerosis: Immune Cells, Histopathology, and Therapeutics;Sclerosis;2024-06-27

3. Documento de consenso de la Sociedad Española de Neurología sobre el tratamiento de la esclerosis múltiple y manejo holístico del paciente 2023;Neurología;2024-03

4. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023;Neurología (English Edition);2024-03

5. Systematic review of gender bias in clinical trials of monoclonal antibodies for the treatment of multiple sclerosis;Neurología (English Edition);2023-11